20537/CRUK_/Cancer Research UK/United Kingdom[Grants and Funding] - Search Results

Year	Number of Results
2014	2
2015	2
2016	3
2017	4
2018	3
2019	3
2020	8
2021	2
2022	4
2023	3
2024	1

1

Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment.

Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Liu R, et al. Antibodies (Basel). 2020 Nov 17;9(4):64. doi: 10.3390/antib9040064. Antibodies (Basel). 2020. PMID: 33212886 Free PMC article. Review.

2

Reducing affinity as a strategy to boost immunomodulatory antibody agonism.

Yu X, Orr CM, Chan HTC, James S, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, Cox KL, Essex JW, Tews I, Glennie MJ, Cragg MS. Yu X, et al. Nature. 2023 Feb;614(7948):539-547. doi: 10.1038/s41586-022-05673-2. Epub 2023 Feb 1. Nature. 2023. PMID: 36725933

3

Editorial: Roles of Fc Receptors in Disease and Therapy.

Ganesan LP, Cragg MS, Vidarsson G. Ganesan LP, et al. Front Immunol. 2020 Jun 12;11:1232. doi: 10.3389/fimmu.2020.01232. eCollection 2020. Front Immunol. 2020. PMID: 32655559 Free PMC article. No abstract available.

4

PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?

Moreno-Vicente J, Beers SA, Gray JC. Moreno-Vicente J, et al. Cancer Lett. 2019 Aug 10;457:74-85. doi: 10.1016/j.canlet.2019.04.025. Epub 2019 May 2. Cancer Lett. 2019. PMID: 31055109 Review.

5

Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives.

Dadas O, Ertay A, Cragg MS. Dadas O, et al. Front Immunol. 2023 Apr 25;14:1147467. doi: 10.3389/fimmu.2023.1147467. eCollection 2023. Front Immunol. 2023. PMID: 37180119 Free PMC article. Review.

6

OX40: Structure and function - What questions remain?

Willoughby J, Griffiths J, Tews I, Cragg MS. Willoughby J, et al. Mol Immunol. 2017 Mar;83:13-22. doi: 10.1016/j.molimm.2017.01.006. Epub 2017 Jan 13. Mol Immunol. 2017. PMID: 28092803 Review.

7

Influence of immunoglobulin isotype on therapeutic antibody function.

Beers SA, Glennie MJ, White AL. Beers SA, et al. Blood. 2016 Mar 3;127(9):1097-101. doi: 10.1182/blood-2015-09-625343. Epub 2016 Jan 13. Blood. 2016. PMID: 26764357 Free PMC article. Review.

8

Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity.

Kennedy PT, Saulters EL, Duckworth AD, Lim YJ, Woolley JF, Slupsky JR, Cragg MS, Ward FJ, Dahal LN. Kennedy PT, et al. Mol Ther. 2024 Feb 7;32(2):457-468. doi: 10.1016/j.ymthe.2023.11.028. Epub 2023 Dec 5. Mol Ther. 2024. PMID: 38053333 Free article.

9

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.

Moreno-Vicente J, Willoughby JE, Taylor MC, Booth SG, English VL, Williams EL, Penfold CA, Mockridge CI, Inzhelevskaya T, Kim J, Chan HTC, Cragg MS, Gray JC, Beers SA. Moreno-Vicente J, et al. J Immunother Cancer. 2022 Jan;10(1):e003735. doi: 10.1136/jitc-2021-003735. J Immunother Cancer. 2022. PMID: 35017153 Free PMC article.

10

TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter.

Turaj AH, Dahal LN, Beers SA, Cragg MS, Lim SH. Turaj AH, et al. Cancer Res. 2017 Jun 15;77(12):3376-3378. doi: 10.1158/0008-5472.CAN-17-0412. Epub 2017 Jun 5. Cancer Res. 2017. PMID: 28584185 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

31 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year